37 results on '"Duygu Ersözlü"'
Search Results
2. Exon 2: Is it the good police in familial mediterranean fever?
- Author
-
Şule Yaşar Bilge, Dilek Solmaz, Soner Şenel, Hakan Emmungil, Levent Kılıç, Sibel Yılmaz Öner, Fatih Yıldız, Sedat Yılmaz, Duygu Ersözlü Bozkırlı, Müge Aydın Tufan, Sema Yılmaz, Veli Yazısız, Yavuz Pehlivan, Cemal Beş, Gözde Yıldırım Çetin, Şükran Erten, Emel Gönüllü, Fezan Şahin, Servet Akar, Kenan Aksu, Umut Kalyoncu, Haner Direskeneli, Eren Erken, Bünyamın Kısacık, Mehmet Sayarlıoğlu, Muhammed Çınar, Timuçin Kaşifoğlu, and İsmail Sarı
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2019
- Full Text
- View/download PDF
3. Disease and treatment-related comorbidities in rheumatoid arthritis
- Author
-
Özlem Doğan Ağbuga and Emine Duygu Ersözlü
- Subjects
rheumatoid arthritis ,comorbidity ,treatment ,Medicine - Abstract
Rheumatoid arthritis (RA) is a chronic, progressive disease affecting systemic connective tissues, including synovial membranes in joints and extra-articular systems. The global prevalence is estimated between 0.5% and 2%, with a higher incidence observed in women, individuals with a family history, and smokers. The disease’s etiology is primarily attributed to immune processes in the synovial membrane and fluid of joints. Importantly, RA is a systemic condition affecting joints, organs, and systems, including the cardiovascular, renal, pulmonary, and neuropsychiatric systems. In one study, 40% of RA patients experienced complications, with a significant incidence of 8.3% among those with cardiovascular disease, interstitial lung disease, osteoporosis, and metabolic syndrome. Sustained inflammation and immune dysregulation, hallmark features of RA, significantly contribute to the onset and progression of associated comorbidities. Comorbidities frequently coexisting with RA encompass cardiovascular diseases, pulmonary disorders, osteoporosis, malignancies, and infections. Such comorbidities exert a direct impact on patient quality of life, functional capacity, and mortality rates. The emergence of these comorbid conditions is not solely attributable to the disease itself but may also be influenced, either positively or negatively, by the therapeutic agents employed.
- Published
- 2024
- Full Text
- View/download PDF
4. Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry
- Author
-
Sibel Zehra Aydın, Gezmiş Kimyon, Cem Özişler, Emine Figen Tarhan, Esen Kasapoğlu Günal, Adem Küçük, Ahmet Omma, Dilek Solmaz, Emine Duygu Ersözlü, Fatih Yıldız, Müge Aydın Tufan, Muhammet Çınar, Rıdvan Mercan, Şule Yavuz, Fatıma Arslan Alhussain, Abdulsamet Erden, Meryem Can, Gözde Yıldırım Çetin, Levent Kılıç, Sibel Bakırcı, Noura Al Osaimi, and Umut Kalyoncu
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2020
- Full Text
- View/download PDF
5. Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database
- Author
-
Duygu Ersözlü, Emine, primary, Ekici, Mustafa, additional, Nihan Coşkun, Belkis, additional, Özlem Badak, Suade, additional, Bilgin, Emre, additional, Kalyoncu, Umut, additional, Yağız, Burcu, additional, Pehlivan, Yavuz, additional, Küçükşahin, Orhan, additional, Erden, Abdulsamet, additional, Solmaz, Dilek, additional, Atagündüz, Pamir, additional, Kimyon, Gezmiş, additional, Beş, Cemal, additional, Çolak, Seda, additional, Mercan, Rıdvan, additional, Kaşifoğlu, Timuçin, additional, Emmungil, Hakan, additional, Alpay Kanıtez, Nilüfer, additional, Ateş, Aşkın, additional, Serdar Koca, Süleyman, additional, Kiraz, Sedat, additional, and Ertenli, İhsan, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
- Author
-
Orhan Küçükşahin, Servet Akar, Emel Gönüllü, Duygu Ersözlü, Sedat Kiraz, Gezmiş Kimyon, Hakan Emmungil, Umut Kalyoncu, Ali İhsan Ertenli, Nihan Coşkun, Emre Bilgin, Rıdvan Mercan, Yavuz Pehlivan, Omer Karadag, Hüseyin Dalkiliç, Cemal Bes, Süleyman Serdar Koca, Burcu Yağız, Nilüfer Alpay Kanıtez, Timuçin Kaşifoğlu, Seda Colak, Elif Durak Ediboglu, Levent Kilic, İç Hastalıkları, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kalyoncu, Umut, Pehlivan, Yavuz, Akar, Servet, Kaşifoğlu, Timuçin, Kimyon, Gezmiş, Karadağ, Ömer, Dalkılıç, Ediz, Ertenli, Ali İhsan, Kılıç, Levent, Ersözlü, Duygu, Beş, Cemal, Emmungil, Hakan, Mercan, Rıdvan, Ediboğlu, Elif Durak, Bilgin, Emre, Çolak, Seda, Koca, Süleyman Serdar, Gönüllü, Emel, Küçükşahin, Orhan, Coşkun, Nihan, Yağız, Burcu, Kiraz, Sedat, Koç University Hospital, and School of Medicine
- Subjects
rheumatoid arthritis ,Male ,Bath ankylosing spondylitis disease activity index ,Inflammatory arthritis ,polymerase chain reaction ,very elderly ,health status ,Disease ,Arthritis, Rheumatoid ,Cohort Studies ,rituximab ,adalimumab ,Pandemic ,middle aged ,disease modifying antirheumatic drug ,Health Assessment Questionnaire ,Prospective Studies ,Registries ,golimumab ,Aged, 80 and over ,register ,Ankylosing Spondylitis Disease Activity Score ,secukinumab ,adult ,medication compliance ,Simplified Disease Activity Index ,Biologic DMARDs ,General Medicine ,spondyloarthritis ,Middle Aged ,cohort analysis ,aged ,female ,spondylarthritis ,Rheumatoid arthritis ,drug withdrawal ,Antirheumatic Agents ,young adult ,Rituximab ,Female ,biologic DMARDs ,medicine.drug ,prospective study ,Adult ,medicine.medical_specialty ,abatacept ,hydroxychloroquine ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,Visual analogue scale ,COVID-19 ,Spondyloarthritis ,salazosulfapyridine ,methotrexate ,Article ,Medication Adherence ,tocilizumab ,coronavirus disease 2019 ,Young Adult ,remission ,Internal medicine ,medicine ,DAS28 ,Humans ,human ,Pandemics ,Aged ,leflunomide ,business.industry ,SARS-CoV-2 ,pandemic ,questionnaire ,General and internal medicine ,visual analog scale ,medicine.disease ,major clinical study ,Discontinuation ,certolizumab pegol ,Bath ankylosing spondylitis functional index ,antirheumatic agent ,observational study ,erythrocyte sedimentation rate ,business ,infliximab ,Crohn Disease Activity Index ,etanercept ,disease activity - Abstract
Background/aim: to evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: a total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: a total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored., Hacettepe Rheumatology Society
- Published
- 2021
7. Women’s past, present, tomorrow in rheumatology
- Author
-
Emine Duygu Ersözlü and Melda Ulaş Güncan
- Subjects
medicine.medical_specialty ,business.industry ,Family medicine ,Internal medicine ,Medicine ,business ,Rheumatology - Published
- 2021
8. Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?
- Author
-
Ufuk İlgen, Ömer Karadağ, Hakan Emmungil, Orhan Küçükşahin, Süleyman Serdar Koca, Abdülsamet Erden, Cemal Bes, Nilüfer Alpay Kanıtez, Ediz Dalkılıç, Servet Akar, Rıdvan Mercan, Muhammet Çınar, Timuçin Kaşifoğlu, Emel Gönüllü, Gezmiş Kimyon, Duygu Ersözlü, Pamir Atagündüz, Levent Kılıç, İhsan Ertenli, Veli Yazısız, Aşkın Ateş, Sedat Kiraz, Umut Kalyoncu, and Ilgen U., KARADAĞ Ö., Emmungil H., KÜÇÜKŞAHİN O., KOCA S. S., ERDEN A., Bes C., Kanitez N. A., DALKILIÇ H. E., AKAR S., et al.
- Subjects
Internal Diseases ,Quantiferon-Tb-Gold ,Sağlık Bilimleri ,İmmünoloji ve Romatoloji ,İç Hastalıkları ,Clinical Medicine (MED) ,Arthritis, Rheumatoid ,Interferon-Gamma Release Tests ,INFECTION ,Immunology and Allergy ,Klinik Tıp (MED) ,CLASSIFICATION CRITERIA ,ROMATOLOJİ ,Clinical-Practice Guidelines ,Klinik Tıp ,Rheumatoid-Arthritis ,QUANTIFERON-TB-GOLD ,GAMMA RELEASE ASSAYS ,Gamma Release Assays ,Tıp ,Antirheumatic Agents ,Medicine ,CLINICAL-PRACTICE GUIDELINES ,Romatoloji ,Infection ,Adult ,Immunology ,Immunology and Rheumatology ,Rheumatology ,Latent Tuberculosis ,Health Sciences ,Spondyloarthritis ,Spondylarthritis ,Humans ,DISEASE-CONTROL ,Classification Criteria ,Biological Products ,Internal Medicine Sciences ,Tuberculin Test ,Arthritis ,Italian Society ,Dahili Tıp Bilimleri ,CLINICAL MEDICINE ,ACTIVE TUBERCULOSIS ,Active Tuberculosis ,RHEUMATOID-ARTHRITIS ,Disease-Control ,Logistic Models ,ITALIAN SOCIETY ,Interferon-gamma Release Tests - Abstract
This study aimed to compare Tuberculin Skin Test (TST) and QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) test in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients scheduled for biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) in a Bacillus Calmette-Guerin-vaccinated population. Adult RA (n = 206) and SpA (n = 392) patients from the TReasure database who had both TST and QFT-GIT prior to initiation of biological and targeted synthetic DMARDs were included in the study. Demographic and disease characteristics along with pre-biologic DMARD and steroid use were recorded. The distribution of TST and performance with respect to QFT-GIT were compared between RA and SpA groups. Pre-biologic conventional DMARD and steroid use was higher in the RA group. TST positivity rates were 44.2% in RA and 69.1% in SpA for a 5 mm cutoff (p < 0.001). Only 8.9% and 15% of the patients with RA and SpA, respectively, tested positive by QFT-GIT. The two tests poorly agreed in both groups at a TST cutoff of 5 mm and increasing the TST cutoff only slightly increased the agreement. Among age, sex, education and smoking status, pre-biologic steroid and conventional DMARD use, disease group, and QFT-GIT positivity, which were associated with a 5 mm or higher TST, only disease group (SpA) and QFT-GIT positivity remained significant in multiple logistic regression. TST positivity was more pronounced in SpA compared to that in RA and this was not explainable by pre-biologic DMARD and steroid use. The agreement of TST with QFT-GIT was poor in both groups. Using a 5 mm TST cutoff for both diseases could result in overestimating LTBI in SpA.
- Published
- 2022
9. Pregnancy in Takayasu's arteritis has a high risk of hypertension-related fetomaternal complications: A retrospective study of a Turkish cohort
- Author
-
Fatma Alibaz-Oner, Gökhan Keser, Kenan Aksu, Nilufer Alpay-Kanitez, Sema Kaymaz Tahra, Duygu Ersözlü, Ayten Yazici, Osman Faruk Bayramlar, Abdulsamet Erden, Sinem Burcu Kocaer, Onay Gercik, Mete Kara, Gökçe Kenar, Haner Direskeneli, Fatos Onen, Servet Akar, Ahmet Omma, and Mehmet Gokhan Gonenli
- Subjects
Adult ,Vasculitis ,medicine.medical_specialty ,Turkey ,Takayasu's arteritis ,Pregnancy Complications, Cardiovascular ,Outcomes ,Preeclampsia ,Rheumatology ,Pre-Eclampsia ,medicine ,Humans ,Risk factor ,Single-Center Experience ,Pregnancy ,Eclampsia ,business.industry ,Obstetrics ,Pregnancy Outcome ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Cohort ,Female ,pregnancy ,business ,Cohort study ,Takayasu arteritis - Abstract
Background This study aimed to examine fetomaternal outcomes in pregnant women in a large Turkish Takayasu arteritis (TAK) cohort and to evaluate the effects of pregnancy on the disease in those patients. Methods This is a cohort study involving 296 pregnancies of 112 TAK patients from 8 tertiary rheumatology centers in Turkey. Pregnancies were divided into 2 groups as pre-d (before disease onset) and post-d (after disease onset). In addition, post-d pregnancies were further divided into 2 subgroups according to fetomaternal complications (FMC) development status. Finally, patients were grouped into those with and without a history of pregnancy after disease onset. Results In post-d pregnancies, rates of worsening hypertension, new-onset hypertension, and preeclampsia were higher than in pre-d pregnancies (0.9% vs 16%, P < .001, 0.5% vs 5.3%, P = .012, and 0% vs 4%, P = .013, respectively). Patients with FMC were more likely to have renal artery involvement (65% vs 21%, P = .003). The patients who had post-d were younger, had longer disease duration, and had more relapses number than other patients (P < .001, P = .028, P = .016, respectively). Vasculitis Damage Index (VDI) results were similar in patients with or without post-d pregnancies. Conclusion Pregnancies after disease onset were found to be associated with HT and preeclampsia/eclampsia. HT-related FMCs are increased in TAK, and patients with renal artery involvement are at higher risk. The number of relapses increases in patients who become pregnant after disease onset, but pregnancy was not an independent risk factor for relapse. Pregnancy after the onset of disease had no negative effect on VDI.
- Published
- 2022
10. Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study
- Author
-
Haner Direskeneli, Omer Karadag, Askin Ates, Abdurrahman Tufan, Nevsun Inanc, Serdar S Koca, Gozde Y Cetin, Servet Akar, Muhammet Cinar, Sedat Yilmaz, Neslihan Yilmaz, Ediz Dalkilic, Cemal Bes, Baris Yilmazer, Ali Sahin, Duygu Ersözlü, Mehmet E Tezcan, Nesrin Sen, Gokhan Keser, Umut Kalyoncu, Berkan Armagan, Basak Hacibedel, Kerem Helvacioglu, Teoman Y Cesur, Canberk S Basibuyuk, Serdar Alkan, Levent Mert Gunay, and DİRESKENELİ R. H. , KARADAĞ Ö., ATEŞ A., TUFAN A., Inanc N., Koca S. S. , Cetin G. Y. , Akar S., Cinar M., Yilmaz S., et al.
- Subjects
Internal Diseases ,Turkish Version ,advanced treatment ,Epidemiology ,Satisfaction ,Drug-Treatment ,Sağlık Bilimleri ,İmmünoloji ve Romatoloji ,İç Hastalıkları ,Clinical Medicine (MED) ,Immunology and Rheumatology ,Medication Adherence ,Validity ,Rheumatology ,Patient Preferences ,Health Sciences ,Compliance-Questionnaire ,Klinik Tıp (MED) ,Adaptation ,ROMATOLOJİ ,ESR ,Internal Medicine Sciences ,Klinik Tıp ,DAS ,Dahili Tıp Bilimleri ,CLINICAL MEDICINE ,Reliability ,switch ,Tıp ,quality of life ,Medicine ,Romatoloji ,RA ,patient preference - Abstract
Objective We aimed to evaluate quality of life (QoL), disease activity, compliance to treatment, patient and physician preferences for route of administration (RoA), status of health and pain in RA patients starting advanced treatments or needing a switch, and the factors associated with patient preferences. Methods A multicentre, prospective, observational and 1-year follow-up study was conducted, between 2015 and 2020, in adult RA patients using advanced treatments for the first time or needing a switch in their current treatments. All the data collected were entered into electronic case report forms. DAS in 28 joints with ESR [DAS28-4(ESR)], EuroQol 5-Dimensional Questionnaire (EQ-5D), HAQ Disability Index (HAQ-DI), Compliance Questionnaire for Rheumatology (CQR-19), Work Productivity and Activity Impairment Instrument (WPAI) and Patient Global Assessment-Visual Analogue Scale (PGA-VAS) questionnaires were used for longitudinal assessments. Results Four hundred and fifty-nine patients were enrolled. Three hundred and eight patients (67.1%) attended the final study visit at 12 months and were included for comparative analyses. Irrespective of RoA, the disease activity and QoL improved significantly at 12 months, whereas compliance worsened. At baseline and 12 months, EQ-5D and DAS28-4(ESR) scores were significantly correlated (P < 0.001). The WPAI scores changed significantly in favour of better outcomes over 12 months after initiation of advanced treatment or switching (P < 0.001). A higher proportion of patients preferred an oral RoA, in comparison to physicians (53.6% vs 31.4%; P < 0.001). Patient and physician RoA preferences were independent of gender, age, disease duration, advanced treatment type and the EQ-5D-3L, DAS28-4(ESR), HAQ-DI, PGA-VAS and CQR-19 scores at baseline. Conclusion The oral route was more frequently preferred by patients compared with physicians, although patients' preference rates showed a slight increase towards the end of the treatment, which might be an important factor for RA outcomes. Better control of disease activity and QoL were achieved at 12 months, regardless of RoA. Lay Summary What does this mean for patients? People with rheumatoid arthritis (RA) and their physicians can have different views throughout the patient journey, whether deciding the main treatment objective, switching a drug or deciding the route of drug administration. However, data are limited in this area. For this purpose, we have conducted a survey study to identify differences between the views of patients and physicians on the management of RA. In this study, we have shown that RA medication compliance decreases over time, irrespective of medication route. This is similar to other studies. We also spotted that there are different routes of drug adminstration (RoA) preferred: a higher proportion of patients preferred an oral RoA compared with physicians (53.6% vs 31.4%, respectively). Patient and physician RoA preferences were not related to gender, age, disease duration, treatment type and disease activity. By surveying patients and physicians at the same time, we have identified their differences better compared with previous studies. Patient preferences should have a major impact on disease management, and the results of this study might encourage patients to discuss their thoughts and preferences with their clinicians to achieve a better outcome., Pfizer; Pleksus CRO Inc., Pfizer has supported funding of this manuscript. Editorial/medical writing support was provided by Pleksus CRO Inc., and it was funded by Pfizer.
- Published
- 2022
11. The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients
- Author
-
Kalyoncu, Umut, Bayindir, Özün, Ferhat Öksüz, Mustafa, Doğru, Atalay, Kimyon, Gezmiş, Tarhan, Emine Figen, Erden, Abdulsamet, Yavuz, Şule, Can, Meryem, Çetin, Gözde Yldrm, Klç, Levent, Küçükşahin, Orhan, Omma, Ahmet, Ozisler, Cem, Solmaz, Dilek, Bozkirli, Emine Duygu Ersözlü, Akyol, Lütfi, Pehlevan, Seval Masatloğlu, Gunal, Esen Kasapoglu, Arslan, Fatos, Ylmazer, Barş, Atakan, Nilgun, and Aydn, Sibel Zehra
- Published
- 2017
- Full Text
- View/download PDF
12. Importance of 14-3-3eta, anti-CarP, and anti-Sa in the diagnosis of seronegative rheumatoid arthritis
- Author
-
Reyhan Bilici Salman, Suade Özlem Badak, Filiz Kibar, Eren Erken, Emine Duygu Ersözlü, Akgün Yaman, Yasar Sertdemir, Baris Boral, Emrah Salman, Alev Çetin Duran, Salih Çetiner, and Çukurova Üniversitesi
- Subjects
Adult ,Male ,Seronegative ,medicine.medical_specialty ,Anti-carP ,14-3-3eta ,14-3-3eta,Anti-carP,Anti Sa,seronegative ,030204 cardiovascular system & hematology ,Gastroenterology ,Anti-Citrullinated Protein Antibodies ,Article ,Arthritis, Rheumatoid ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Vimentin ,Serologic Tests ,Carp ,Autoantibodies ,Seronegative rheumatoid arthritis ,Autoimmune disease ,0303 health sciences ,biology ,Receiver operating characteristic ,030306 microbiology ,business.industry ,Autoantibody ,Area under the curve ,General Medicine ,Middle Aged ,Anti Sa ,biology.organism_classification ,medicine.disease ,Confidence interval ,Cross-Sectional Studies ,14-3-3 Proteins ,Rheumatoid arthritis ,Female ,Carbamates ,business - Abstract
PubMedID: 31651120 Background/aim: Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation. The study aimed to assess serum 14-3-3eta, anti-CarP, and anti-Sa in seronegative RA (SNRA) patients who were treatment-naïve as well as in healthy subjects. This is the first study in the literature to examine these autoantibodies together in SNRA patients. Materials and methods: Forty-five treatment-naïve SNRA patients and 45 healthy subjects were recruited. Drugs change the levels of autoantibodies; therefore, patients who took any medication had been excluded from our study. Anti-carbamylated protein, anti-Sa, and 14-3-3eta were measured by using three different ELISA kits. Results: Median serum concentration of healthy controls in 14-3-3eta was 0.02 (0.02–0.27) ng/mL. Median serum concentration of SNRA patients in 14-3-3eta was 1.00 (0.48–1.28) ng/mL. Data were analyzed with Mann–Whitney U tests; the P-value was
- Published
- 2019
13. Clinical and laboratory factors associated with the bamboo spine in patients with axial spondyloarthritis: are there clues for the bamboo spine?
- Author
-
Pamir Atagündüz, Sedat Kiraz, Servet Akar, Orhan Küçükşahin, Abdulsamet Erden, Aysun Aksoy, Belkis Nihan Coşkun, Burcu Yağiz, Cemal Bes, Nilüfer Alpay Kanitez, Levent Kilic, Ömer Karadağ, Timuçin Kaşifoğlu, Hakan Emmungil, Muhammet Cinar, Gezmiş Kimyon, Veli Yazisiz, Aşkın Ateş, Duygu Ersözlü, Emel Gönüllü, Rıdvan Mercan, İhsan Ertenli, Umut Kalyoncu, and Atagündüz P., KİRAZ S., Akar S., KÜÇÜKŞAHİN O., Erden A., AKSOY A., COŞKUN B. N., YAĞIZ B., Bes C., Alpay Kanitez N., et al.
- Subjects
Internal Diseases ,Immunology ,Life Sciences (LIFE) ,Sağlık Bilimleri ,İmmünoloji ve Romatoloji ,İç Hastalıkları ,Clinical Medicine (MED) ,Immunology and Rheumatology ,Rheumatology ,Yaşam Bilimleri ,Health Sciences ,ALERJİ ,Immunology and Allergy ,Klinik Tıp (MED) ,ROMATOLOJİ ,Internal Medicine Sciences ,Klinik Tıp ,İmmünoloji ,Temel Bilimler ,Life Sciences ,Dahili Tıp Bilimleri ,CLINICAL MEDICINE ,Tıp ,ALLERGY ,Yaşam Bilimleri (LIFE) ,Medicine ,İmmünoloji ve Alerji ,Natural Sciences ,Romatoloji - Abstract
OBJECTIVES: To analyse the clinical and laboratory factors associated with bamboo spine. METHODS: Data of patients fulfilling the 2009 ASAS classification criteria for axial spondyloarthritis, registered in the national, multicentre, longitudinal, and observational database of TReasure was analysed. Radiographs were assessed using the Bath Ankylosing Spondylitis Radiologic Index (BASRI). Data of patients with a bamboo spine (Group 1) was compared to data derived from patients with a longstanding disease of at least 15 years but no syndesmophytes (Group 2). RESULTS: Out of the 5060 patients, 1246 had eligible radiographs. There were 111 patients (8.9%) with a bamboo spine. Male sex was more common among patients with bamboo spine. The median BMI of 27.7 (25.8-31.1) in Group1 was higher than the BMI of 25.9 (22.9-29.2) in Group 2 (p
- Published
- 2021
14. In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?
- Author
-
Yavuz Pehlivan, Emre Bilgin, Servet Akar, Gezmiş Kimyon, Belkıs Nihan Coşkun, Abdulsamet Erden, Burcu Yağız, Ediz Dalkilic, Sedat Kiraz, Nilüfer Alpay Kanıtez, Timuçin Kaşifoğlu, Ertugrul Cagri Bolek, Omer Karadag, Rıdvan Mercan, Ihsan Ertenli, Cemal Bes, Ahmet Karataş, Veli Yazisiz, Şule Yaşar Bilge, Hakan Emmungil, Sedat Yilmaz, Orhan Küçükşahin, Duygu Ersözlü, Emel Gönüllü, Umut Kalyoncu, and Bahar Kelesoglu
- Subjects
Male ,medicine.medical_specialty ,Turkey ,Visual analogue scale ,Immunology ,Disease ,Arthritis, Rheumatoid ,Rheumatology ,Internal medicine ,medicine ,Immunology and Allergy ,Rheumatoid factor ,Humans ,Pain Management ,Prospective Studies ,Glucocorticoids ,business.industry ,Middle Aged ,medicine.disease ,Target dose ,Rheumatoid arthritis ,Antirheumatic Agents ,Cohort ,Drug Therapy, Combination ,Female ,Antirheumatic drugs ,business - Abstract
We wanted to see how close we could get to our goal of treating rheumatoid arthritis (RA) without the use of glucocorticoids (GCs) in the disease-modifying antirheumatic drugs (DMARDs) era using real-life data. Established in 2017, the TReasure database is a web-based, prospective, observational cohort for Turkey. As of May 2019, there were 2,690 RA patients recorded as receiving biologic and targeted synthetic DMARDs (bDMARDs and tsDMARDs) therapy. At the start of the bDMARDs or tsDMARDs, patients with follow-up visits of at least 3 months were registered. At the time of registration and the last visit, doses of GCs were recorded and it was determined if the target dose of ≤ 7.5 mg was achieved. During registration and follow-up, 23.4% of the patients did not receive GCs and 76.5% of the patients received GCs at any time. GCs could be stopped after 59 (25–116) months in 28.4% of these patients, but 71.6% of patients were still using GC. The target GC dose could not be achieved in 18.2% of these patients (n = 352). The rate of continuing to use GC was significantly higher in women, in the elderly, those with rheumatoid factor (RF) positive, with higher Visual Analog Scale (VAS) pain and Disease Activity Score (DAS)-28. The initial GC dose of ≥ 7.5 mg/day was found to be crucial in not reaching the GC target dose (p
- Published
- 2021
15. Switching between biological DMARDs and associated reasons in rheumatoid arthritis and spondyloarthritis treatments: TReasure study-real life data
- Author
-
Omer Karadag, Emre Tekgöz, Süleyman Serdar Koca, Müge Aydın Tufan, Onay Gercik, Hüseyin Dalkiliç, Şükran Erten, Pınar Kızılırmak, Levent Kilic, Umut Kalyoncu, Ayşe Bahar Keleşoğlu Dinçer, Belkıs Nihan Coşkun, Burak Öz, Gezmiş Kimyon, Abdulsamet Erden, Yavuz Pehlivan, Veli Yazisiz, Emel Gönüllü, Sedat Yilmaz, Servet Akar, Nazife Sule Yasar Bilge, Orhan Küçükşahin, Duygu Ersözlü, Ali İhsan Ertenli, Sedat Kiraz, Rıdvan Mercan, Mustafa Ender Terzioğlu, Aşkın Ateş, Nilüfer Alpay Kanıtez, Timuçin Kaşifoğlu, Muhammet Cinar, Cemal Bes, Hakan Emmungil, and Burcu Yağız
- Subjects
medicine.medical_specialty ,business.industry ,Rheumatoid arthritis ,medicine ,Treasure ,Intensive care medicine ,medicine.disease ,business ,Real life data - Published
- 2019
16. Tuberculin Skin Test in Spondyloarthritis: Overestimated if Rheumatoid Arthritis Guidelines for Latent Tuberculosis Are Used?
- Author
-
Emel Gönüllü, Rıdvan Mercan, Süleyman Serdar Koca, Gezmiş Kimyon, Cemal Bes, Veli Yazisiz, Sedat Kiraz, Orhan Küçükşahin, Abdulsamet Erden, Duygu Ersözlü, Servet Akar, Umut Kalyoncu, Hakan Emmungil, Aşkın Ateş, Ufuk İlgen, Nilüfer Alpay Kanıtez, Timuçin Kaşifoğlu, Muhammet Cinar, Ihsan Ertenli, Ediz Dalkilic, Omer Karadag, Levent Kilic, and Pamir Atagündüz
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,Latent tuberculosis ,business.industry ,Rheumatoid arthritis ,medicine ,Tuberculin ,Skin test ,bacterial infections and mycoses ,medicine.disease ,business ,Dermatology - Abstract
Background: Several societies published recommendations for latent tuberculosis infection (LTBI) screening before biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) but not for other inflammatory arthritides such as spondyloarthritis (SpA). Using RA guidelines could result in overestimating Tuberculin Skin Test (TST) positivity in SpA. This study aimed to compare the distribution of TST results in SpA and RA patients along with comparison in terms of QuantiFERON®-TB Gold In-Tube (QFT-GIT) test in a Bacillus Calmette-Guérin-vaccinated population.Methods: Adult RA (n=206) and SpA (n=392) patients from the TReasure database who had both TST and QFT-GIT prior to initiation of biological and targeted synthetic DMARDs were included in the study. Demographic and disease characteristics along with pre-biologic DMARD and steroid use were recorded. The distribution of TST and performance with respect to QFT-GIT were compared between RA and SpA groups.Results: Pre-biologic conventional DMARD and steroid use was higher in the RA group. TST positivity rates were 44.2% in RA and 69.1% in SpA for a 5 mm cut-off (pConclusions: TST positivity was more pronounced in SpA compared to that in RA and this was not explainable by pre-biologic DMARD and steroid use. The agreement of TST with QFT-GIT was poor in both groups. Using a 5 mm TST cut-off for both diseases could result in overestimating LTBI in SpA.
- Published
- 2020
17. Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results
- Author
-
Ihsan Ertenli, Nilufer Alpay-Kanitez, Burcu Yağız, Ediz Dalkilic, Omer Karadag, Veli Yazisiz, Hakan Emmungil, Sedat Kiraz, Emre Tekgöz, Nazife Sule Yasar Bilge, Abdulsamet Erden, Levent Kilic, Pamir Atagündüz, Belkıs Nihan Coşkun, Gezmiş Kimyon, Emel Gönüllü, Rıdvan Mercan, Cemal Bes, Süleyman Serdar Koca, Aşkın Ateş, Timuçin Kaşifoğlu, Muhammet Cinar, Servet Akar, Ufuk İlgen, Orhan Küçükşahin, Duygu Ersözlü, Umut Kalyoncu, and Yavuz Pehlivan
- Subjects
musculoskeletal diseases ,Adult ,Male ,medicine.medical_specialty ,Time Factors ,Turkey ,03 medical and health sciences ,Psoriatic arthritis ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,In patient ,Spondylitis, Ankylosing ,Referral and Consultation ,030304 developmental biology ,Retrospective Studies ,Related factors ,0303 health sciences ,Ankylosing spondylitis ,business.industry ,Incidence ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Prognosis ,Uveitis, Anterior ,stomatognathic diseases ,Ophthalmology ,Rheumatoid arthritis ,Cohort ,Acute Disease ,030221 ophthalmology & optometry ,Female ,business ,Uveitis ,Follow-Up Studies - Abstract
Spondyloarthritis (SpA) is a group of diseases with overlapping skeletal and extra-articular features. Acute anterior uveitis (AAU) is the most common extra-articular manifestation of SpA. The relation between AAU and SpA is well defined in the current literature. Our study aims to analyze the frequency and factors associated with AAU in different forms of SpA in a large nationwide cohort of Turkish SpA patients.Retrospective cohort study.The data were obtained from the TReasure database, which compiles data from records of the web-based Rheumatoid Arthritis (RA) and SpA patients treated with biological disease-modifying anti-rheumatismal drugs from different regions of Turkey. The clinical characteristics of SpA and uveitis are recorded.Data of the 4,297 SpA patients were included in the study. Overall, 475 of 4,297 patients (11.0%) had experienced 1 or more episodes of uveitis. SpA patients with older age (P.001), a smoking history (P = .004), delayed diagnosis (P = .001), longer disease duration (P.001), arthritis (P.001), positive HLA-B27 (P.001), a family history of SpA (P.001), and radiographic damage (presence of sacroiliitis, syndesmophytes, bamboo spine, hip involvement) (P.001 for all) more commonly had uveitis. On the other hand, uveitis was less prevalent in patients with psoriasis and psoriatic arthritis (P.001 for both).Uveitis may be the key feature leading to SpA diagnosis. Patients with radiographic damage and long disease duration have an increased risk for uveitis in both male and female SpA patients. Patients with uveitis should be referred to a rheumatologist for a thorough evaluation of SpA.
- Published
- 2020
18. Association of disease characteristics with the temporal sequence of skin and musculoskeletal disease onset in psoriatic arthritis
- Author
-
Emel Gönüllü, Gezmiş Kimyon, S. Pehlevan, Sule Yavuz, Atalay Dogru, Kenan Aksu, Dilek Solmaz, Levent Kilic, Emine Duygu Ersözlü, M. Cinar, Ilaria Tinazzi, Veli Yazisiz, Ediz Dalkilic, Suleyman Yilmaz, Sibel Bakirci, Emre Bilgin, Ahmet Omma, Orhan Küçükşahin, Ozun Bayindir, Rıdvan Mercan, Koray Tascilar, Umut Kalyoncu, Emine Figen Tarhan, A. Erden, Tuncay Duruöz, Gozde Yildirim Cetin, Cem Ozisler, Serpil Ergulu Esmen, Sibel Zehra Aydin, Müge Aydın Tufan, Meryem Can, Şükran Erten, Abdurrahman Tufan, Timuçin Kaşifoğlu, Fatih Yildiz, Adem Kucuk, Ayse Balkarli, and Servet Akar
- Subjects
medicine.medical_specialty ,integumentary system ,business.industry ,Arthritis, Psoriatic ,Dermatology ,Psoriatic disease ,Musculoskeletal disease ,medicine.disease ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Psoriatic skin ,Psoriatic arthritis ,0302 clinical medicine ,Psoriasis ,Humans ,Medicine ,Disease characteristics ,Musculoskeletal Diseases ,business ,Skin - Abstract
The temporal relationship between the onset of skin psoriasis (Pso) and psoriatic arthritis (PsA) is a long and well-known feature of psoriatic disease. Psoriatic skin lesions emerge years before the development of musculoskeletal manifestations in nearly 75% of PsA patients. While skin and joint manifestations develop within one year in 15-20% of the patients, joint manifestations precede the skin involvement by a year or more in about 10% of the patients (1).
- Published
- 2021
19. Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry
- Author
-
Abdulsamet Erden, Esen Kasapoglu Gunal, Sibel Zehra Aydin, Cem Ozisler, Ahmet Omma, Sibel Bakirci, Müge Aydın Tufan, Meryem Can, Noura Al Osaimi, Rıdvan Mercan, Dilek Solmaz, Umut Kalyoncu, Emine Figen Tarhan, Emine Duygu Ersözlü, Gozde Yildirim Cetin, Fatıma Arslan Alhussain, Sule Yavuz, Levent Kilic, Gezmiş Kimyon, Fatih Yildiz, Adem Kucuk, Muhammet Cinar, and MÜ
- Subjects
Body surface area ,lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,business.industry ,psoriasis ,registry ,medicine.disease ,Real life data ,Rheumatology ,Validity ,Psoriatic arthritis ,International database ,Internal medicine ,Psoriasis ,Brodalumab ,medicine ,Original Article ,Patient-reported outcome ,business ,lcsh:RC581-607 ,Signs ,disease activity - Abstract
Yildiz, Fatih/0000-0003-3628-8870; Cinar, Muhammet/0000-0002-6150-3539 WOS: 000537230800003 PubMed ID: 31922480 Objective: Our aim is to test the validity of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome, to assess the psoriasis severity within the scope of rheumatology. Methods: Within the PsA international database (PSART-ID), 571 patients had PSI, while 322 of these also showed body surface area (BSA). Correlations between PSI, BSA, and other patient- and physician-reported outcomes were investigated. Results: There was a good correlation between PSI and BSA (r=0.546, p
- Published
- 2020
20. Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease
- Author
-
Atallah Al‐Onazi, Umut Kalyoncu, Sibel Bakirci, Abdulsamet Erden, Sule Yavuz, Levent Kilic, Ahmet Omma, Cem Ozisler, Fatih Yildiz, Dilek Solmaz, Emine Duygu Ersözlü, Muhammet Cinar, Müge Aydın Tufan, Seval Pehlevan, Gezmiş Kimyon, Ediz Dalkilic, Emine Figen Tarhan, Servet Akar, Atalay Dogru, Meryem Can, Sema Yilmaz, Esen Kasapoglu Gunal, Emel Gönüllü, Sibel Zehra Aydin, Orhan Küçükşahin, Gözde Çetin, Ozun Bayindir, Ege Üniversitesi, Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı., Dalkılıç, Ediz, CMF-4757-2022, Selçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, and Yılmaz, Sema
- Subjects
Male ,Data base ,Nail disease ,Arthritis ,Disease ,Anamnesis ,Procedures ,urologic and male genital diseases ,0302 clinical medicine ,Deformity ,Enthesitis ,Medicine ,Registries ,Disease activity ,Family history ,Middle aged ,Skin ,Medical history taking ,Incidence ,Pustulosis Palmoplantaris ,Secukinumab ,Nail Diseases ,Register ,Multicenter study ,Athology ,Clinical trial ,Phenotype ,Psoriatic arthritis ,Female ,Sex ,medicine.symptom ,Human ,Adult ,medicine.medical_specialty ,Genetic predisposition to disease ,Follow-up studies ,Major clinical study ,Lower risk ,Article ,Arthritis, psoriatic ,03 medical and health sciences ,Rheumatology ,Psoriasis ,Genetics ,Humans ,Prospective study ,Psoriasis vulgaris ,030203 arthritis & rheumatology ,business.industry ,Genetic predisposition ,Odds ratio ,Follow up ,medicine.disease ,Dermatology ,Onset age ,Risk factors ,Clinical feature ,Risk factor ,business ,Prospective studies ,Controlled study - Abstract
WOS: 000505281300007, PubMed: 30680951, Objective Psoriatic arthritis (PsA) has a genetic background. Approximately 40% of patients with psoriasis or PsA have a family history of psoriasis or PsA, which may affect disease features. The aim of this study was to assess the effects of family history of psoriasis and PsA on disease phenotypes. Methods Data from 1,393 patients recruited in the longitudinal, multicenter Psoriatic Arthritis International Database were analyzed. The effects of family history of psoriasis and/or PsA on characteristics of psoriasis and PsA were investigated using logistic regression. Results A total of 444 patients (31.9%) had a family history of psoriasis and/or PsA. These patients were more frequently women, had earlier onset of psoriasis, more frequent nail disease, enthesitis, and deformities, and less frequently achieved minimal disease activity. Among 444 patients, 335 only had psoriasis in their family, 74 had PsA, and 35 patients were not certain about having PsA and psoriasis in their family, so they were excluded from further analysis. In the multivariate analysis, family history of psoriasis was associated with younger age at onset of psoriasis (odds ratio [OR] 0.976) and presence of enthesitis (OR 1.931), whereas family history of PsA was associated with lower risk of plaque psoriasis (OR 0.417) and higher risk of deformities (OR 2.557). Family history of PsA versus psoriasis showed increased risk of deformities (OR 2.143) and lower risk of plaque psoriasis (OR 0.324). Conclusion Family history of psoriasis and PsA impacts skin phenotypes, musculoskeletal features, and disease severity. The link between family history of psoriasis/PsA and pustular/plaque phenotypes may point to a different genetic background and pathogenic mechanisms in these subsets., Turkish Society for Rheumatology; Scientific and Technological Research Council of TurkeyTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK), Supported by the Turkish Society for Rheumatology. Dr. Bakirci's work was supported by the Scientific and Technological Research Council of Turkey and the Turkish Society for Rheumatology.
- Published
- 2020
21. Turkish Society for Rheumatology recommendations for the management of axial spondyloarthritis
- Author
-
Sinem Nihal Esatoglu, Lale Ocal, Didem Arslan Tas, Emine Duygu Ersözlü, Nurdan Kötevoğlu, Fatoş Önen, A. Akdogan, Pamir Atagündüz, Sedat Kiraz, Aksiyel Spondiloartrit Tedavi Önerileri Türkiye Romatoloji Derneği, Servet Akar, Gulen Hatemi, and Turan Hilmi Yeşil
- Subjects
medicine.medical_specialty ,business.industry ,Turkish ,Internal medicine ,language ,Physical therapy ,Medicine ,Axial spondyloarthritis ,business ,Rheumatology ,language.human_language - Published
- 2018
22. POS0935 DO PERIPHERAL AND EXTRA MUSCULOSKELETAL MANIFESTATIONS HAVE AN IMPACT ON BIOLOGIC DMARD PRESCRIBING PATTERNS IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF TREASURE EXPERIENCE
- Author
-
Burcu Yağız, Sinan Koca, Emel Gönüllü, Omer Karadag, Cemal Bes, Emre Tekgöz, G. Kabadayi, T. Kasifoglu, Belkıs Nihan Coşkun, Ali İhsan Ertenli, M. Cinar, Gezmiş Kimyon, E. Durak Ediboglu, Rıdvan Mercan, Orhan Küçükşahin, Servet Akar, N. S. Yasar Bilge, Duygu Ersözlü, Aşkın Ateş, Nilüfer Alpay Kanıtez, Yavuz Pehlivan, Dilek Solmaz, Seda Colak, Umut Kalyoncu, Sedat Kiraz, Veli Yazisiz, Hakan Emmungil, and Pamir Atagündüz
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,General Biochemistry, Genetics and Molecular Biology ,Rheumatology ,Peripheral ,Internal medicine ,medicine ,Immunology and Allergy ,Biologic DMARD ,Axial spondyloarthritis ,Treasure ,business - Abstract
Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Extra musculoskeletal manifestations (EMMs; uveitis [AAU], inflammatory bowel disease [IBD] and psoriasis [Pso] are among the most common ones) are important features and might have an impact on the disease burden in patients with axSpA. The presence of EMM, in particular IBD and AAU could influence the choice of TNFi however little is known regarding the role of peripheral manifestations together with the EMM on the prescribing patterns in axSpA patients.Objectives:To examine the frequency of peripheral and EMMs in a real-world axSpA cohort and their effect on the choice of first advanced treatment.Methods:In total 1687 axSpA patients (58% male and the mean age (±SD) was 38.5 ± 10.9) who initiated his/her first biologic were included in the present analysis. The data for the current study was obtained from the TReasure web-based registry; in which RA and SpA patients treated with bDMARDs from different regions of Turkey. Baseline demographic, disease related characteristics, peripheral and EMMs were extracted. Characteristics of patients with and without peripheral/extra-musculoskelatal involvement were compared as well as factors/covariates associated with the choice of first TNFi and secukinumab was analysed.Results:Enthesis (28.2%) was found the most common peripheral manifestations and peripheral arthritis (26.4%) and hip arthritis (24.4%) followed it. Symptom duration to the first advanced treatment initiation was significantly shorter in axSpA patients with peripheral arthritis, enthesitis, dactylitis and psoriasis and longer in hip arthritis and AAU. HLA-B27 positivity was significantly lower in patients with arthritis, psoriasis and IBD and higher with hip arthritis and AAU. In multivariate analysis the presence of IBD is significantly associated with the preference of monoclonal TNFi (mab) over etanercept (ETA) (OR 5,770; 95%CI 1.788-18.616). However ETA was preferred in patients with hip arthritis (p=0.003), longer symptom duration (p=0.049), and using sulfasalazine (p=0.043). In comparison with mabs, secukinumab (SEC) prescription was found to be significantly associated with higher age (p=0.001), sulfasalazin (p=0.001) and methotrexate usage (p=0.053) among axSpA patients need their first advanced treatment.Conclusion:The results of the current study confirm the pathophsyologic associations of peripheral involvement and EMM in axSpA patients. Apart from hip arthritis the presence of IBD has an impact on the prescription of advanced treatment in real-life.Table 1.Clinical characteristics of patients in cohortAll patients(n=1678)Peripheral arthritis(n=445)Dactilitis(n=81)Enthesis(n=476)Uveitis(n=193)Psoriazis(n=152)IBD(n=78)Hip involvemet(n=412)Age, mean±SD38,5±10,938,3±11,637,4±11,137,9±10,741,3±11,439,9±11,341,6±12,239,2±11,2Male sex,n (%)974 (57,7)184 (41,3)34 (42)238 (50)96 (49,7)54 (35,5)43 (55,1)272 (66)Symptom duration, mean month±SD108,5±98,996,9±92,979,1±76,5100,4±92,7144,7±110,287,7±9494,5±98133,3±108,2HLA B27 positivity, n (%)621 (53,7)142 (46,3)27 (51,9)174 (49,4)104 (77)34 (36,2)16 (27,1)186 (59,8)Concomitant cDMARD usage (yes), n (%)420 (24,9)170 (38,2)39 (48,1)133 (27,9)53 (27,5)58 (38,2)24 (30,8)99 (24)BASDAİ,mean±SD5,1±2,55,1±35,3±3,15,3±2,94,7±2,55,6±2,44,8±2,35,3±2,1ASDAS-CRP, mean±SD3,1±1,52,6±1,92,5±1,82,8±1,72,9±1,73,4±1,33,1±1,53,7±1,4Disclosure of Interests:None declared
- Published
- 2021
23. The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients
- Author
-
Ozun Bayindir, Seval Pehlevan, Levent Kılıç, Nilgün Atakan, Baris Yilmazer, Mustafa Ferhat Öksüz, Orhan Küçükşahin, Emine Duygu Ersözlü Bozkirli, Umut Kalyoncu, Cem Ozisler, Abdulsamet Erden, Esen Kasapoglu Gunal, Ahmet Omma, Lütfi Akyol, Gezmiş Kimyon, Gozde Yildirim Cetin, Sibel Zehra Aydin, Fatos Arslan, Dilek Solmaz, Emine Figen Tarhan, Meryem Can, Atalay Dogru, Sule Yavuz, iç Hastalıkları, Ege Üniversitesi, and OMÜ
- Subjects
Male ,Turkey ,Disease ,registry ,Recommendations ,Severity of Illness Index ,030207 dermatology & venereal diseases ,0302 clinical medicine ,Disease-Activity ,Activities of Daily Living ,Prevalence ,Pharmacology (medical) ,Registries ,Fatigue ,psoriatic arthritis ,Remission Induction ,Clinical History ,Middle Aged ,Classification ,Health-Care ,Prostate-specific antigen ,Antirheumatic Agents ,Female ,Adult ,medicine.medical_specialty ,Disease activity ,External validity ,Ankylosing-Spondylitis ,03 medical and health sciences ,Joint disease ,Psoriatic arthritis ,Age Distribution ,Rheumatology ,Internal medicine ,Psoriasis ,Spondyloarthritis ,medicine ,Humans ,Patient Reported Outcome Measures ,Sex Distribution ,030203 arthritis & rheumatology ,Health Services Needs and Demand ,Tumor Necrosis Factor-alpha ,business.industry ,Arthritis, Psoriatic ,medicine.disease ,Criteria ,Physical therapy ,Inflammatory Back-Pain ,business ,disease activity - Abstract
WOS: 000397050600018, PubMed ID: 27794533, Objective. The aim was to assess the characteristics of PsA, find out how well the disease is controlled in real life, demonstrate the treatments and identify the unmet needs. Methods. The PsA registry of Turkey is a multicentre Web-based registry established in 2014 and including 32 rheumatology centres. Detailed data regarding demographics for skin and joint disease, disease activity assessments and treatment choices were collected. Results. One thousand and eighty-one patients (64.7% women) with a mean (S.D.) PsA duration of 5.8 (6.7) years were enrolled. The most frequent type of PsA was polyarticular [437 (40.5%)], followed by oligoarticular [407 (37.7%)] and axial disease [372 (34.4%)]. The mean (S.D.) swollen and tender joint counts were 1.7 (3) and 3.6 (4.8), respectively. Of these patients, 38.6% were on conventional synthetic DMARD monotherapy, 7.1% were on anti-TNF monotherapy, and 22.5% were using anti-TNF plus conventional synthetic DMARD combinations. According to DAS28, 86 (12.4%) patients had high and 105 (15.2%) had moderate disease activity. Low disease activity was achieved in 317 (45.7%) patients, and 185 (26.7%) were in remission. Minimal disease activity data could be calculated in 247 patients, 105 of whom (42.5%) had minimal disease activity. The major differences among sexes were that women were older and had less frequent axial disease, more fatigue, higher HAQ scores and less remission. Conclusion. The PsA registry of Turkey had similarities with previously published registries, supporting its external validity. The finding that women had more fatigue and worse functioning as well as the high percentage of active disease state highlight the unmet need in treatment of PsA.
- Published
- 2016
24. AB0723 SMOKING MAY BE RELATED TO SACROILIITIS IN ENTEROPATHIC ARTHRITIS PATIENTS: TREASURE REAL-LIFE PRELIMINARY DATA
- Author
-
Sedat Yilmaz, Orhan Küçükşahin, Duygu Ersözlü, Veli Yazisiz, Aşkın Ateş, Nilüfer Alpay Kanıtez, Rıdvan Mercan, Timuçin Kaşifoğlu, Burak Öz, Muhammet Cinar, Ali İhsan Ertenli, Gezmiş Kimyon, Zeynel Abidin Akar, Ediz Dalkilic, Cemal Bes, Yavuz Pehlivan, Servet Akar, Hakan Emmungil, Nazife Sule Yasar Bilge, Koray Tascilar, Umut Kalyoncu, Burcu Yağız, Şükran Erten, Süleyman Serdar Koca, Levent Kilic, Pamir Atagündüz, Abdulsamet Erden, Ender Terzioglu, Bahar Kelesoglu, Ufuk İlgen, Müge Aydın, Onay Gercik, Sedat Kiraz, Omer Karadag, and Belkis Nihan Seniz
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,Epidemiology ,medicine ,Sacroiliitis ,Arthritis ,In patient ,Smoking status ,Antirheumatic drugs ,business ,medicine.disease - Abstract
Background: Articular manifestations may differ in ulcerative colitis (UC) and Crohn’s disease (CD). Genetic and non-genetic factors like sex, smoking, and presence of HLA-B27 were previously shown to modify the expression of articular and other extraintestinal manifestations of IBD. Objectives: The aim of this study is to document disease features and factors affecting the expression of articular manifestations in Turkish patients with IBD-related (enteropathic) arthritis under treatment with disease modifying antirheumatic drugs (DMARDs). Methods: Data regarding enteropathic arthritis (EA) were collected from the TReasure database, a nation-wide multicenter observational registry of inflammatory arthritis patients. Results: Among 4066 patients with seronegative spondyloarthropaties (SpA), 156 (3.8%) had EA, not reflecting a true prevalence due to selection bias. Demographic and clinical features according to IBD groups were summarized in Table 1. Rates of presence of sacroiliitis were similar between patients with UC and CD (39.9% and 60.1%, p=0.086 respectively). Rates of HLA-B27 positivity were 31.6% and 7.1% in patients with and without radiographic sacroiliitis, respectively (p=0.101). Enthesitis, dactylitis, psoriasis, family history forSpA, ESR, CRP, BASDAI and aSDAS levels had similar distributions in patients with and without radiographic sacroiliitis. Rates of “never-smoked” (26.5% vs 64.7%) and “current smoking” (32.4% vs 17.6%) significantly differed in patients with and without sacroiliitis (overall p=0.012) Conclusion: Our data confirm an association between smoking status and disease manifestations, particularly radiographic sacroiliitis. References [1] Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol2009; 15: 2449-2455. Disclosure of interests: Orhan Kucuksahin: None declared, abdulsamet Erden: None declared, Ufuk Ilgen: None declared, Sedat Kiraz: None declared, ali Ihsan Ertenli: None declared, Nazife Sule Yasar Bilge: None declared, Timucin Kasifoglu: None declared, Ediz Dalkilic Grant/research support from: MSD and abbvie, Consultant for: MSD, abbvie,Roche, UCB, Pfizer and Novartis, Speakers bureau: MSD, abbvie,Roche, UCB, Pfizer and Novartis, Cemal Bes: None declared, Nilufer alpay Kanitez: None declared, Hakan Emmungil Grant/research support from: MSD, Roche, Pfizer, abbvie, Consultant for: Novartis, Roche, Speakers bureau: MSD, Roche, Pfizer, abbvie,Celltrion, Novartis, Pamir atagunduz: None declared, Belkis Nihan Seniz: None declared, Burcu Yagiz: None declared, Suleyman Serdar Koca: None declared, Muhammet Cinar: None declared, askin ates: None declared, Servet akar Grant/research support from: MSD, abbvie, Roche, UCB, Novartis, Pfizer, amgen, Consultant for: MSD, abbvie, Roche, UCB, Novartis, Pfizer, amgen, Speakers bureau: Pfizer, Onay Gercik: None declared, Duygu Ersozlu: None declared, Veli yazisiz: None declared, Gezmis Kimyon: None declared, Muge aydin: None declared, Ridvan Mercan: None declared, Burak Oz: None declared, Zeynel abidin akar: None declared, Omer Karadag: None declared, Bahar Kelesoglu: None declared, Sedat Yilmaz: None declared, Yavuz Pehlivan: None declared, Ender Terzioglu: None declared, Levent Kilic: None declared, Sukran Erten: None declared, Koray Tascilar: None declared, Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer, Consultant for: MSD, abbvie, Roche, UCB, Novartis, Pfizer and abdi Ibrahim, Speakers bureau: MSD, abbvie, Roche, UCB, Novartis, Pfizer and abdi Ibrahim
- Published
- 2019
25. FRI0098 SWITCHING RATE OF BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS PATIENTS: TREASURE – REAL LIFE DATA
- Author
-
Süleyman Serdar Koca, Rıdvan Mercan, Burcu Yağız, Ali İhsan Ertenli, Aşkın Ateş, Nilüfer Alpay Kanıtez, Omer Karadag, Abdulsamet Erden, Yavuz Pehlivan, Sedat Yilmaz, Orhan Küçükşahin, Timuçin Kaşifoğlu, Ufuk İlgen, Onay Gercik, Gezmiş Kimyon, Duygu Ersözlü, Belkıs Nihan Coşkun, Muhammet Cinar, Cemal Bes, Şükran Erten, Ender Terzioglu, Ediz Dalkilic, Levent Kilic, Pamir Atagündüz, Ayşe Bahar Keleşoğlu Dinçer, Umut Kalyoncu, Sedat Kiraz, Hakan Emmungil, Servet Akar, Nazife Sule Yasar Bilge, Veli Yazisiz, Müge Aydın, Burak Öz, and Zeynel Abidin Akar
- Subjects
medicine.medical_specialty ,Median time ,business.industry ,Disease duration ,Rheumatoid arthritis ,Internal medicine ,medicine ,Treatment options ,Biologic DMARD ,medicine.disease ,business ,Real life data ,Biologic Agents - Abstract
Background: In rheumatoid arthritis (RA), biologic DMARDs are important treatment options in resistant patients. Inefficacy or side effects may cause switching between these drugs. Objectives: This study aimed to determine features of patients switching from one biologic DMARD to another in RA treatment and to investigate associated reasons for switching. Methods: This multicenter, prospective observational cohort study used the TReasure database in which web-based registration of RA and spondyloarthritis patients are being performed in 15 centers across different regions of Turkey. In this study, data of RA patients switching from one biologic agent to another were analyzed. Demographic and clinical data, follow-up duration, time to switch, and reasons for switching were retrieved from the database. Results: Of the included 2115 RA patients, 829 (39.2%) switched between biologic agents (switched group) and 1286 (60.8%) continued to receive their current therapies (continued group). The median follow-up duration of all patients was 3.7 years and the median time to switch was 1.1 years. In the switched group, the proportion of females and the median HAQ-DI score were higher as well as disease duration was longer (Table 1). Among the biologic agents used at first, 60.9% of the patients were receiving an anti-TNF agent and 39.1% of the patients were receiving other biologic agents (Table 2, figure 1). In the switched group (n=829), the main reasons for switching were secondary inefficacy (n=269), primary inefficacy (n=238), and side effects (n=178) followed by primary or secondary unknown inefficacy (n=30), patient’s demand (n=21), physician’s request (n=16), willing to be pregnant (n=7), other (n=31), and unknown (n=54). Conclusion: The patients in the Treasure database were followed-up approximately 4 years and about one-third of the patients had to switch from one biologic DMARD to another. The main reasons for this switching were primary (29.2%) and secondary (33.0%) inefficacy and 20% of the patients had to switch due to side effects. According to the switching pattern, about half of the patients using an anti-TNF agent at first switched to another anti-TNF agent and the other half switched to other biologic agents. Disclosure of Interests: Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, Speakers bureau: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, Ali Ihsan Ertenli: None declared, Abdulsamet Erden: None declared, Orhan Kucuksahin: None declared, Timucin Kasifoglu: None declared, Ediz Dalkilic Grant/research support from: MSD and Abbvie, Consultant for: MSD, Abbvie,Roche, UCB, Pfizer and Novartis, Speakers bureau: MSD, Abbvie,Roche, UCB, Pfizer and Novartis, Cemal Bes: None declared, Nilufer Alpay Kanitez: None declared, Hakan Emmungil Grant/research support from: MSD, Roche, Pfizer, Abbvie, Consultant for: Novartis, Roche, Speakers bureau: MSD, Roche, Pfizer, Abbvie,Celltrion, Novartis, Pamir Atagunduz: None declared, Belkis Nihan Coskun: None declared, Burcu Yagiz: None declared, Suleyman Serdar Koca: None declared, Muhammet Cinar: None declared, Askin Ates: None declared, Servet Akar Grant/research support from: MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Speakers bureau: Pfizer, Onay Gercik: None declared, Duygu Ersozlu: None declared, Veli Yazisiz: None declared, Gezmis Kimyon: None declared, Muge Aydin: None declared, Ridvan Mercan: None declared, Burak Oz: None declared, Nazife Sule Yasar Bilge: None declared, Zeynel Abidin Akar: None declared, Omer Karadag: None declared, Ayse Bahar Kelesoglu Dincer: None declared, Sedat Yilmaz: None declared, Ufuk Ilgen: None declared, Yavuz Pehlivan: None declared, Ender Terzioglu: None declared, Levent Kilic: None declared, Sukran Erten: None declared, Sedat Kiraz: None declared
- Published
- 2019
26. FRI0395 SWITCHING RATE OF ANTI-TNF AGENTS IN SPONDYLOARTHRITIS PATIENTS: TREASURE – REAL LIFE DATA
- Author
-
Yavuz Pehlivan, Cemal Bes, Müge Aydın, Ali İhsan Ertenli, Ediz Dalkilic, Zeynel Abidin Akar, Belkıs Nihan Coşkun, Abdulsamet Erden, Umut Kalyoncu, Ayşe Bahar Keleşoğlu Dinçer, Gezmiş Kimyon, Servet Akar, Nazife Sule Yasar Bilge, Onay Gercik, Hakan Emmungil, Burcu Yağız, Ufuk İlgen, Veli Yazisiz, Burak Öz, Aşkın Ateş, Nilüfer Alpay Kanıtez, Timuçin Kaşifoğlu, Muhammet Cinar, Sedat Yilmaz, Orhan Küçükşahin, Duygu Ersözlü, Omer Karadag, Süleyman Serdar Koca, Levent Kilic, Pamir Atagündüz, Şükran Erten, Sedat Kiraz, Rıdvan Mercan, and Ender Terzioglu
- Subjects
medicine.medical_specialty ,Median time ,business.industry ,Internal medicine ,Disease duration ,medicine ,Treatment options ,business ,Real life data ,Cohort study - Abstract
Background In spondyloarthritis (SpA), biologic DMARDs are important treatment options in resistant patients. Inefficacy or side effects may cause switching between these drugs. Objectives This study aimed to determine features of patients switching from one biologic agent to another in SpA treatment and to investigate associated reasons. Methods This multicenter, prospective observational cohort study used the TReasure database in which web-based registration of rheumatoid arthritis and SpA patients are being performed in 15 centers across different regions of Turkey. In this study, data of SpA patients switching from one biologic agent to another were analyzed. Demographic and clinical data, follow-up duration, time to switch, and reasons for switching were retrieved from the database. Kaplan-Meier analysis was performed to show drug retention rates and Cox regression analysis was performed to investigate the factors affecting switching. Results Of the included 3138 SpA patients, 1165 (37.1%) switched to another biologic agent (switched group) and 1973 (62.9%) continued to receive their current therapies (continued group). The median follow-up duration of all patients was 3.8 years and the median time to switch was 1.0 years (0-13.4 years). According to the distribution of comorbidities, the rates of patients having diabetes mellitus, hyperlipidemia, asthma, gastrointestinal bleeding, and cancer were significantly higher in the switched group than those of in the continued group (8.4% vs. 5.8%, p=0.006; 14.5% vs. 9.2%, p In the switched group (n=1165), the main reasons for switching were secondary inefficacy (n=351), primary inefficacy (n=328), and side effects (n=267) followed by primary or secondary unknown inefficacy (n=57), physician’s request (n=45), patient’s demand (n=36), willing to be pregnant (n=9), other (n=37), and unknown (n=70). Conclusion In SpA patients, switching was frequent between anti-TNF agents and the median time to first switch was 1 year. Female gender, short disease duration, and lower BASDAI score were found to be the significant factors affecting switching from the anti-TNF agent used at first. The main reasons for this switching were primary (29.0%) and secondary (31.0%) inefficacy followed by side effects (23.6%). Switching between subcutaneous anti-TNF agents is generally less than switching from infliximab to another biologic agent. Disclosure of Interests Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, Speakers bureau: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, Sedat Kiraz: None declared, Abdulsamet Erden: None declared, Orhan Kucuksahin: None declared, Timucin Kasifoglu: None declared, Ediz Dalkilic Grant/research support from: MSD and Abbvie, Consultant for: MSD, Abbvie,Roche, UCB, Pfizer and Novartis, Speakers bureau: MSD, Abbvie,Roche, UCB, Pfizer and Novartis, Cemal Bes: None declared, Nilufer Alpay Kanitez: None declared, Hakan Emmungil Grant/research support from: MSD, Roche, Pfizer, Abbvie, Consultant for: Novartis, Roche, Speakers bureau: MSD, Roche, Pfizer, Abbvie,Celltrion, Novartis, Pamir Atagunduz: None declared, Belkis Nihan Coskun: None declared, Burcu Yagiz: None declared, Suleyman Serdar Koca: None declared, Muhammet Cinar: None declared, Askin Ates: None declared, Servet Akar Grant/research support from: MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Speakers bureau: Pfizer, Onay Gercik: None declared, Duygu Ersozlu: None declared, Veli Yazisiz: None declared, Gezmis Kimyon: None declared, Muge Aydin: None declared, Ridvan Mercan: None declared, Burak Oz: None declared, Nazife Sule Yasar Bilge: None declared, Zeynel Abidin Akar: None declared, Omer Karadag: None declared, Ayse Bahar Kelesoglu Dincer: None declared, Sedat Yilmaz: None declared, Ufuk Ilgen: None declared, Yavuz Pehlivan: None declared, Ender Terzioglu: None declared, Levent Kilic: None declared, Sukran Erten: None declared, Ali Ihsan Ertenli: None declared
- Published
- 2019
27. AB0761 DEMOGRAPHIC AND CLINICAL FEATURES OF JUVENILE-ONSET PSORIATIC ARTHRITIS: RESULTS FROM PsART-ID REGISTRY
- Author
-
Umut Kalyoncu, Emel Gönüllü, Sibel Bakirci, M. Cinar, S. Ergulu Eşmen, Ahmet Omma, Cem Ozisler, Gezmiş Kimyon, Servet Akar, Meryem Can, Orhan Küçükşahin, Levent Kılıç, S. Pehlevan, Ediz Dalkilic, Senol Yavuz, Suna Aydin, Duygu Ersözlü, Dilek Solmaz, Esen Kasapoglu, Atalay Dogru, Mehmet Tuncay Duruöz, Abdurrahman Tufan, A. Erden, O. Bayindir, Fusun Yildiz, Sevdiye Ersoy Yilmaz, and Emine Figen Tarhan
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Enthesitis ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,Dactylitis ,Psoriatic arthritis ,Rheumatology ,Internal medicine ,Psoriasis ,Cohort ,Immunology and Allergy ,Medicine ,Juvenile ,medicine.symptom ,business ,BASFI ,BASDAI - Abstract
Background:Although psoriatic arthritis (PsA) may be seen at any decades, juvenil onset PsA is relatively rare. Moreover, there were no more data about clinical features, treatments, and course in juvenile PsA when they reached to adult age.Objectives:The objective of this study was to assess and compare demographic and clinical features for juvenile onset PsA and adult onset PsA.Methods:PsART-ID is a multicenter, international database, investigating the disease characteristic in real life (1). Briefly, demographic data, PsA subtypes, uveitis, enthesitis, dactylitis, Co-morbidities, disease activity scores (TJC, SJC, VAS-pain, VAS patients and physician global assessments, VAS-fatigue, BASDAI), and functional status (HAQ-DI, BASFI) were recorded. Psoriasis and PsA starting age were noted, as well. Patients were classified as juvenile PsA or juvenile PsO (under 18 years old). Results were compared regarding to juvenile versus adult onset age.Results:Overall, 1644 PsA patients were included to study, 301/1644 (18.3%) patients had juvenile onset psoriasis. Of 39/1644 (2.4%) patients had juvenile onset PsA, as well. As expected, juvenile onset PsA patients were younger, however PsA disease duration were longer than adult onset PsA patients. There were no any difference between demographic and clinical data, except BMI and enthesitis were less frequently at the juvenile onset PsA groups. Although, ever csDMARD using were similar between two groups, however, juvenile onset PsA patients were used more frequently bDMARDs.Table.Comparison of demographic and clinical characteristics of juvenile and adult-onset psoriatic arthritisJuvenile onsetAdult onsetpN (%)39 (2.4)1605 (97.6)Female Sex n (%)24 (61.5)1006 (62.7)0.884PsA beginning age mean (SD)13.3 ± 3.8542.3 ± 12.9Current age mean (SD)26.6 ±10.747.3 ±13.07Duration of psoriasis (years)17.10 ± 11.2614.75 ± 11.780.124Duration of psoriatic arthritis (years)13.5 ±115.06 ± 6.7Cigarette smoking (ever) n (%)15/38641/14940.72Education duration/year (mean,SD)10.09 ± 3.679.52 ± 4.810.464BMI (kg/m2) (mean, SD)24.5 ±5.128.3 ± 5.21Family history of PsO/PsA n (%)15 (38.5)559 (34.9)0.642Nail involvement n (%)18 (46.2)762 (47.5)0.864Dactilitis n (%)9 (23.7)367 (24)0.958Entesitis n (%)3 (7.9)384 (25.7)0.013Uveitis n (%)-13 (4.3)0.713Axial involvement (%)15 (38.5)464 (29)0.199Methotrexate36 (92.3)1348 (84)0.162Sulfasalazine17 (43.6)612 (38.1)0.488Leflunomide14 (35.9)379 (23.6)0.076Biologic DMARDs102 (33.9)358 (26.8)0.013Conclusion:Although psoriasis may be seen frequently in the juvenile age, juvenile onset PsA was not so frequent in our PsA cohort. Although, ever csDMARD using were similar between two groups, however, juvenile onset PsA patients were used bDMARDs more frequently.References:[1]Kalyoncu U et al. The Psoriatic Arthritis Registry of Turkey: results of a multicenter registry on 1081 patients. Rheumatology. 2017;56:279-286.Disclosure of Interests:Serpil ERGULU EŞMEN: None declared, Ozun Bayindir: None declared, esen kasapoğlu: None declared, Sibel Bakirci: None declared, Dilek Solmaz: None declared, Gezmiş Kimyon: None declared, Atalay Doğru: None declared, Ediz Dalkiliç: None declared, Cem Özişler: None declared, Meryem Can: None declared, Servet Akar: None declared, Emine Figen Tarhan: None declared, Sule Yavuz: None declared, Levent Kiliç: None declared, Orhan Küçükşahin: None declared, Ahmet Omma: None declared, Emel Gönüllü: None declared, Fatih Yildiz: None declared, Duygu Ersözlü: None declared, abdurrahman tufan: None declared, Muhammet Çinar: None declared, Abdulsamet Erden: None declared, Sema Yilmaz: None declared, Seval Pehlevan: None declared, Mehmet Tuncay Duruöz: None declared, Sibel Aydin: None declared, Umut Kalyoncu Consultant of: Abbvie, Amgen, Janssen, Lilly, Novartis, UCB
- Published
- 2020
28. THU0285 The effect of family history on disease phenotypes in 1393 psoriatic arthritis patients
- Author
-
Sibel Bakirci Ureyen, Orhan Küçükşahin, Senol Yavuz, Ahmet Omma, Servet Akar, O. Bayindir, Emel Gönüllü, Suna Aydin, Gezmiş Kimyon, A. Erden, Atalay Dogru, S. Pehlevan, Umut Kalyoncu, Levent Kılıç, Ediz Dalkilic, Tuncay Duruöz, Esen Kasapoglu Gunal, Cem Ozisler, Gozde Yildirim Cetin, Sevdiye Ersoy Yilmaz, Müge Aydın Tufan, M. Cinar, Emine Figen Tarhan, Dilek Solmaz, Meryem Can, Emine Duygu Ersözlü, and Fusun Yildiz
- Subjects
medicine.medical_specialty ,business.industry ,Parenteral transmission ,Enthesitis ,Disease ,medicine.disease ,Psoriatic arthritis ,Internal medicine ,Relative risk ,Psoriasis ,medicine ,Family history ,medicine.symptom ,Clinical phenotype ,business - Abstract
Background Psoriatic arthritis (PsA) has a genetic background, approximately 40% of patients having a family history of psoriasis or PsA in first-degree relatives, which may impact the disease features. Objectives The aim of this study was to evaluate the effects of family history of psoriasis or PsA on the disease phenotypes. Methods The demographic and clinical data were retrieved from the longitudinal, multicenter PsArt-ID (Psoriatic Arthritis-International Database). Family history of psoriasis and PsA were investigated for 1st and 2nd degree relatives separately. The effect of the family history of psoriasis and/or PsA on disease phenotypes and severity were analysed, calculating the relative risks (RR). Results 1393 patients had the data for family history, 444 (31.9%) of whom was positive for psoriasis and/or PsA. The majority of the family history was only psoriasis (333/444; 75%) and 58.5% (260/444) of the patients had first-degree relatives affected. There was no differences in maternal or parental transmission rates however women had more psoriasis and/or PsA in their family (67.3% vs 32.7% p: 0.028). Patients with a family history had an earlier onset of age for psoriasis (29±14.8 vs 31±14.9 p: 0.007), more frequent nail involvement (50.7% vs 29.6% p: 0.032), more frequent enthesitis (28.2% vs 17.7% p Conclusions The family history of psoriasis and PsA has impacts on skin phenotypes, musculoskeletal features and the disease severity. The differences between family history of psoriasis and PsA and pustular vs plaque phenotypes may point out to a different genetic background and pathogenic mechanisms in these subsets. Disclosure of Interest None declared
- Published
- 2018
29. SAT0353 Geographical differences in psoriatic arthritis: a transatlantic comparison
- Author
-
Senol Yavuz, Levent Kılıç, Gozde Yildirim Cetin, Fusun Yildiz, Orhan Küçükşahin, Esen Kasapoglu Gunal, Meryem Can, Sevdiye Ersoy Yilmaz, Umut Kalyoncu, S. Pehlevan, Emine Figen Tarhan, O. Bayindir, Ahmet Omma, Emel Gönüllü, A. Erden, Sibel Bakirci Ureyen, Atalay Dogru, Servet Akar, Müge Aydın Tufan, Emine Duygu Ersözlü, M. Cinar, Cem Ozisler, Gezmiş Kimyon, Dilek Solmaz, Ediz Dalkilic, Tuncay Duruöz, and Suna Aydin
- Subjects
Psoriatic arthritis ,International database ,business.industry ,Treatment choices ,Patient characteristics ,Medicine ,In patient ,Disease characteristics ,Polyarthritis ,Disease ,business ,medicine.disease ,Demography - Abstract
Background The environmental and genetic factors play a crucial role in the pathogenesis of psoriatic arthritis (PsA) which may cause a difference in disease characteristics for patients from different geographical regions. Objectives The aim of the study was to explore the disease characteristics, treatment choices and comorbidities in patients with PsA in different countries to see the impact of geographic factors. Methods PsArt-ID (Psoriatic Arthritis- International Database) is a prospective, multicentre registry in PsA, which was initially developed in Turkey in 2014, with participation of Canada since 2015 and Italy since 2017. Patients with PsA are consecutively registered to this registry with the aim of investigating the real-life data. Patient characteristics across Turkey (n=1283) and Canada (n=119) are compared for this analysis. Results Canadian patients were older at the time of recruitment (Table). They also were more frequently smokers, had higher duration of education and higher BMI than patients in Turkey. Patients in Canada had more frequent polyarthritis (66.7% vs 39.6%, p Conclusions Geographical differences have impacts on the disease features in PsA, which may be due to genetic, environmental and cultural differences. The treatments are comparable suggesting a similar approach by the physicians. Disclosure of Interest None declared
- Published
- 2018
30. Diagnostic Importance of 14-3-3η protein, anti-CarP and anti-Sa in Seronegative Rheumatoid Arthritis
- Author
-
Reyhan Bilici Salman, Filiz Kibar, Emine Duygu Ersözlü, Baris Boral, Emrah Salman, Akgün Yaman, Suade Özlem Badak, Eren Erken, Yasar Sertdemir, Alev Çetin Duran, and Salih Çetiner
- Subjects
biology ,business.industry ,Immunology ,medicine ,General Medicine ,medicine.disease ,business ,Carp ,biology.organism_classification ,Omics ,Juvenile rheumatoid arthritis ,Seronegative rheumatoid arthritis - Published
- 2018
31. MEFV gen mutasyonunun 2. ya da 10. ekzonda olması ailevi Akdeniz ateşi hastalığının seyrinde etkili midir?
- Author
-
ŞENEL, SONER, SARI, İSMAİL, KAŞİFOĞLU, NİLGÜN, KAŞİFOĞLU, TİMUÇİN, SAYARLIOĞLU, MEHMET, ERKEN, EREN, DİRESKENELİ, RAFİ HANER, KALYONCU, UMUT, AKSU, KENAN, AKAR, SERVET, ŞAHİN, FEZAN, GÖNÜLLÜ, EMEL, ERTEN, ŞÜKRAN, YILDIRIM ÇETİN, GÖZDE, BES, CEMAL, PEHLİVAN, YAVUZ, YAZISIZ, VELİ, YILMAZ, SEMA, tufan, müge aydın, bozkırlı, duygu ersözlü, YILMAZ, SEDAT, YILDIZ, FATİH, ÖNER, sibel yılmaz, KILIÇ, LEVENT, EMMUNGİL, HAKAN, SOLMAZ, DİLEK, and YAŞAR BİLGE, NAZİFE ŞULE
- Published
- 2017
32. The effect of infliximab on depressive symptoms in patients with ankylosing spondylitis
- Author
-
Emine Duygu Ersözlü-Bozkırlı, Sakir Ozgür Keşkek, Emre Bozkırlı, and Ahmet Eftal Yücel
- Subjects
lcsh:Immunologic diseases. Allergy ,lcsh:Internal medicine ,depression ,ankylosing spondylitis ,infliximab ,lcsh:RC31-1245 ,lcsh:RC581-607 - Abstract
Objectives: Ankylosing spondylitis is a chronic inflammatory disease which physically, psychologically, and socially affects the patient's life. Previous studies have reported a correlation between ankylosing spondylitis and depression. In this study we investigated the effect of infliximab on depression in ankylosing spondylitis patients. Methods: A total of 29 patients with ankylosing spondylitis were enrolled in this prospective study. Infliximab was administered intravenously at a dose of 5 mg/kg at baseline, weeks 2 and 6. The measurements of morning stiffness, modified Schober’s test, chest expansion, erythrocyte sedimentation rate, C-reactive protein, Bath ankylosing spondylitis disease activity index, Bath ankylosing spondylitis functional index and Beck depression inventory scores were compared with baseline and 12th week. Results: The modified Schober’s test and chest expansion increased, the morning stiffness duration, erythrocyte sedimentation rate and C-reactive protein levels decreased after infliximab treatment (p < 0.001, respectively). There was statistically significant decrease in Bath ankylosing spondylitis disease activity index, Bath ankylosing spondylitis functional index and Beck depression invantory scores of patients after 12 weeks (p < 0.001, respectively). Conclusion: Infliximab can improve depression and its symptoms in patients with ankylosing spondylitis.
- Published
- 2015
33. Exon 2: Is it the good police in familial mediterranean fever?
- Author
-
Bilge, Şule Yaşar, Solmaz, Dilek, Şenel, Soner, Emmungil, Hakan, Kılıç, Levent, Öner, Sibel Yılmaz, Yıldız, Fatih, Yılmaz, Sedat, Bozkırlı, Duygu Ersözlü, Tufan, Müge Aydın, Yılmaz, Sema, Yazısız, Veli, Pehlivan, Yavuz, Beş, Cemal, Çetin, Gözde Yıldırım, Erten, Şükran, Gönüllü, Emel, Şahin, Fezan, Akar, Servet, and Aksu, Kenan
- Subjects
FAMILIAL Mediterranean fever - Abstract
Objective: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Most of the identified disease-causing mutations are located on exon 10. As the number of studies about the effect of the exonal location of the mutation and its phenotypic expression is limited, we aimed to investigate whether the exonic location of the Mediterranean fever (MEFV) mutation has an effect on the clinical manifestation in patients with FMF. Methods: Study population was derived from the main FMF registry that included 2246 patients from 15 different rheumatology clinics. We categorized the mutations according to their exon locations and retrieved the clinical and demographic information from the database. Results: Patients having the MEFV mutations on exon 2 or 10 (n:1526) were divided into three subgroups according to the location of the MEFV mutations: Group 1 (exon 2 mutations), Group 2 (exon 10 mutations), and Group 3 (both exon 2 and exon 10 mutations). Group 2 patients were of a significantly younger age at onset, and erysipel-like erythema, arthritis, amyloidosis, and a family history of FMF were more common in this group. Conclusion: Patients with FMF and exon 10 mutations show more severe clinical symptoms and outcome. Exon 2 mutations tend to have a better outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Exon 2: Is it the good police in familial mediterranean fever?
- Author
-
Bilge, Şule Yaşar, Solmaz, Dilek, Şenel, Soner, Emmungil, Hakan, Kılıç, Levent, Öner, Sibel Yılmaz, Yıldız, Fatih, Yılmaz, Sedat, Bozkırlı, Duygu Ersözlü, Tufan, Müge Aydın, Yılmaz, Sema, Yazısız, Veli, Pehlivan, Yavuz, Beş, Cemal, Çetin, Gözde Yıldırım, Erten, Şükran, Gönüllü, Emel, Şahin, Fezan, Akar, Servet, and Aksu, Kenan
- Abstract
Objective: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Most of the identified disease-causing mutations are located on exon 10. As the number of studies about the effect of the exonal location of the mutation and its phenotypic expression is limited, we aimed to investigate whether the exonic location of the Mediterranean fever (MEFV) mutation has an effect on the clinical manifestation in patients with FMF. Methods: Study population was derived from the main FMF registry that included 2246 patients from 15 different rheumatology clinics. We categorized the mutations according to their exon locations and retrieved the clinical and demographic information from the database. Results: Patients having the MEFV mutations on exon 2 or 10 (n:1526) were divided into three subgroups according to the location of the MEFV mutations: Group 1 (exon 2 mutations), Group 2 (exon 10 mutations), and Group 3 (both exon 2 and exon 10 mutations). Group 2 patients were of a significantly younger age at onset, and erysipel-like erythema, arthritis, amyloidosis, and a family history of FMF were more common in this group. Conclusion: Patients with FMF and exon 10 mutations show more severe clinical symptoms and outcome. Exon 2 mutations tend to have a better outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. Anti-Tümör Nekroz Faktör Alfa Tedavisi ve Tüberkülin Cilt Testi
- Author
-
Bozkırlı, Emine Duygu Ersözlü, primary, Tufan, Müge Aydın, additional, Özışık, Lale, additional, Şen, Nazan, additional, and Yücel, Ahmet Eftal, additional
- Published
- 2015
- Full Text
- View/download PDF
36. Kronik ITP tanısıyla izlenen hastada saptanan Sjögren sendomu.
- Author
-
Bozkırlı, Emine Duygu Ersözlü and Açık, Didar Yanardağ
- Abstract
Amaç: Sjögren sendromu (SS); egzokrin bezlerin, özellikle de tükürük-gözyaşı bezlerinin, fokal lenfosittik infiltrasyonu ile karakterize, etyolojisi bilinmeyen, kronik otoimmün bir hastalıktır. Primer olabildiği gibi, RA, SLE, sklerodermaya sekonder olarak da gelişebilir. SS diğer otoimmün hastalıklarla da birliktelik gösterebilir. SS ile en sık otoimmün tiroid hastalıkları birlikteliği tanımlanmıştır. Bir hastada birden fazla otoimmün hastalığın aynı anda olması poliotoimmünite olarak adlandırılmıştır. Bizim hastamızda da SS ve ITP birlikteliği saptanmıştır. Olgu: Otuz sekiz yaşında kadın hasta ANA pozitifliği nedeniyle yönlendirildi. Öyküsünden 5 yıl önce gebelik sırasında ITP tanısı aldığı, aralıklı olarak steroid tedavisi uygulandığı ve splenektomi olduğu öğrenildi. Hematoloji polikliniğine ılımlı trombositopeni nedeni ile başvurmuştu ve metilprednizolon 1x16 mg olarak kullanmaktaydı. Sistem sorgulamasında; inflamatuvar eklem ağrısı, ağız kuruluğu, göz kuruluğu ve raynoud ile uyumlu şikayetleri mevcuttu. Fizik muayenesi doğaldı. Yapılan göz muayenesinde Schirmer sağ gözde 5, solda 4 mm olarak saptandı. Laboratuvarında; hemoglobin 12 g/dl, beyaz küre 4150/mm³, trombosit 118 bin, ANA 1/320 granüler paternde pozitif, RF, SSA ve SSB pozitif olarak saptandı. Sedimantasyon hızı 35 mm/h ve CRP: 0.3 mg/dl olarak saptandı. Biyokimyasal değerler, C3, C4, tam idrar tetkiki sonuçları normaldi. Diğer ENA paneli ise negatif olarak saptandı. Hastanın gebelik dönemine ait tektik sonuçları incelendiğinde Ana testinin negatif olduğu görüldü. Hasta minör tükrük bezi biyopsisini kabul etmedi. Mevcut bulgularla hastaya Sjögren sendromu tanısı konuldu ve tedavisine hidroksiklorokin 2x200 mg eklendi. Sonuç: Immün trombositopenili olgularda ITP tanısının bir dışlama tanısı olduğu ve özellikle steroide dirençli vakalarda altta yatan bağ doku hastalıklarının ekarte edilmesi gerektiği bilinmektedir. Bizim vakamızda olduğu gibi bazı hastalarda ise otoimmun hastalık birlikteliği şeklinde iki hastalık da aynı hastada saptanabilmektedir. Otoimmün hastalıklar immün toleransın bozulması sonucu gelişmekte ve hastada başka bir otoimmün hastalık gelişme riski de artmaktadır. Sonuç olarak, otoimmün hastalığı olan bireylerde başka otoimmün hastalık varlığı açısından dikkatli olunmalı ve hastanın mevcut bulguları göz önüne alınarak gerekli taramalar yapılmalıdır. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
37. Towards a standardized program of transitional care for adolescents with juvenile idiopathic arthritis for Turkey: a national survey study
- Author
-
Betül Sözeri, Nihal Şahin, Ceyhun Açarı, Pinar Ozge Avar Aydın, Ozge Baba, Esra Bağlan, Sevcan Bakkaloğlu, Sibel Bakırcı, Yelda Bilginer, Burcu Yücel Bozkaya, Şengül Çağlayan, Mustafa Çakan, Figen Çakmak, Taner Coşkuner, Ferhat Demir, Fatma Gül Demirkan, Şeyda Doğantan, Hatice Adıgüzel Dündar, Emine Duygu Ersözlü, Sercan Gücenmez, Oğuz Gürler, Rana İşgüder, Adem Küçük, Mukaddes Kalyoncu, Levent Kılıç, Sara Şebnem Kılıç, Hakan Kısaoğlu, Ayşenur Paç Kısaarslan, Zehra Kızıldağ, Duygu Kurtuluş, Semanur Özdel, Kübra Öztürk, Pelin Şenol, Ayşe Tanatar, Sema Nur Taşkın, Fatma Tuncer Kuru, Serkan Türkuçar, Kadir Ulu, Erbil Ünsal, Ayten Yazıcı, Deniz Gezgin Yıldırım, Selçuk Yüksel, Özgür Kasapçopur, Seza Özen, Nuray Aktay Ayaz, and Hafize Emine Sönmez
- Subjects
Adolescent ,Arthritis ,Juvenile ,Chronic disease ,Transition to adult care ,Pediatrics ,RJ1-570 ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background Juvenile idiopathic arthritis (JIA) is a prevalent childhood chronic arthritis, often persisting into adulthood. Effective transitional care becomes crucial as these patients transition from pediatric to adult healthcare systems. Despite the concept of transitional care being recognized, its real-world implementation remains inadequately explored. This study aims to evaluate the thoughts and practices of healthcare providers regarding transitional care for JIA patients. Methods A cross-sectional survey was conducted among pediatric and adult rheumatologists in Turkey. Based on the American Academy of Pediatrics’ six core elements of transitional care, the survey included 86 questions. The respondents’ demographic data, attitudes towards transitional care, and practical implementation were assessed. Results The survey included 48 rheumatologists, with 43.7% having a transition clinic. The main barriers to establishing transition programs were the absence of adult rheumatologists, lack of time, and financial constraints. Only 23.8% had a multidisciplinary team for transition care. Participants agreed on the importance of coordination and cooperation between pediatric and adult healthcare services. The timing of the transition process varied, with no consensus on when to initiate or complete it. Participants advocated for validated questionnaires adapted to local conditions to assess transition readiness. Conclusions The study sheds light on the challenges and perspectives surrounding transitional care for JIA patients in Turkey. Despite recognized needs and intentions, practical implementation remains limited due to various barriers. Cultural factors and resource constraints affect the transition process. While acknowledging the existing shortcomings, the research serves as a ground for further efforts to improve transitional care and ensure better outcomes for JIA patients transitioning into adulthood.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.